BC
Elite in Acute Myeloid Leukemia (AML)

Dr. Brenda W. Cooper

University Hospitals Cleveland Medical Center
Cleveland, OH
Elite
 in Acute Myeloid Leukemia (AML)
Specialties:Hematology Oncology
Experience:39 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

    View 63 More Conditions +
    Check Dr. Brenda W. Cooper's experience treating your condition:
    About Dr. Brenda W. Cooper

    Brenda Cooper is a Hematologist Oncology expert in Cleveland, Ohio. Cooper has been practicing medicine for over 39 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 36 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Ohio. Cooper is currently accepting new patients.

    Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 26 clinical trials in the past 15 years. In particular, she has co-authored 21 articles and participated in 13 clinical trials in the study of Acute Myeloid Leukemia (AML).

    Insurance

    MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brenda W. Cooper it is best to call her office and ask if your insurance is accepted.

    Accepts Medicare
    Call to see if your plan is accepted.
    Locations
    11100 Euclid Ave, Cleveland, OH 44106
    Other Locations
    5885 Landerbrook Dr, Suite 100, Mayfield Heights, OH 44124
    3909 Orange Pl, Beachwood, OH 44122
    Background & Education
    Graduate Institution
    Johns Hopkins University School Of Medicine, 1984
    Specialties
    Hematology Oncology
    Licenses
    Internal Medicine in OH
    Hospital Affiliations
    University Hospitals Cleveland Medical Center
    University Hospitals Geauga Medical Center
    University Hospitals Ahuja Medical Center
    University Hospitals Richmond Medical Center
    University Hospitals Parma Medical Center
    University Hospitals Geneva Medical Center
    Languages Spoken
    English
    Gender
    Female
    Clinical Research

    Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

    26 Clinical Trials
    A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
    Enrollment Status: Recruiting
    Publish Date: December 13, 2022
    Intervention Type: Biological, Drug
    Study Drugs: VOR33Mylotarg
    Study Phase: Phase 1/Phase 2
    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
    Enrollment Status: Recruiting
    Publish Date: December 09, 2022
    Intervention Type: Other, Biological, Drug
    Study Drugs: DaratumumabDexamethasoneLenalidomide
    Study Phase: Phase 3
    A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
    Enrollment Status: Recruiting
    Publish Date: December 07, 2022
    Intervention Type: Drug, Other, Procedure
    Study Drugs: CarmustineCyclophosphamideCytarabineEtoposideIbrutinibMelphalan
    Study Phase: Phase 3
    Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
    Enrollment Status: Recruiting
    Publish Date: October 20, 2022
    Intervention Type: Drug
    Study Drugs: DFP-10917CytarabineAzacitidineDecitabineMitoxantroneEtoposideFludarabineIdarubicinVenetoclaxCladribine
    Study Phase: Phase 3
    A Long-term Follow-up Study of Patients Who Received VOR33
    Enrollment Status: Recruiting
    Publish Date: August 10, 2022
    Intervention Type: Genetic
    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
    Enrollment Status: Recruiting
    Publish Date: April 20, 2022
    Intervention Type: Biological
    Study Phase: Phase 2
    Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: December 09, 2022
    Intervention Type: Drug
    Study Drugs: TAK-981Rituximab
    Study Phase: Phase 1/Phase 2
    Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
    Enrollment Status: Active, not recruiting
    Publish Date: November 21, 2022
    Intervention Type: Drug
    Study Drugs: GilteritinibMidostaurinDaunorubicinCytarabine
    Study Phase: Phase 2
    Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
    Enrollment Status: Active, not recruiting
    Publish Date: September 02, 2022
    Intervention Type: Biological, Other
    Study Drug: Nivolumab
    Study Phase: Phase 2
    A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
    Enrollment Status: Active, not recruiting
    Publish Date: July 20, 2022
    Intervention Type: Other, Drug, Biological
    Study Drugs: IbrutinibObinutuzumabVenetoclax
    Study Phase: Phase 3
    A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.
    Enrollment Status: Completed
    Publish Date: June 30, 2022
    Intervention Type: Drug, Other
    Study Phase: Phase 1/Phase 2
    A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
    Enrollment Status: Active, not recruiting
    Publish Date: May 31, 2022
    Intervention Type: Drug
    Study Drugs: PevonedistatVenetoclaxAzacitidine
    Study Phase: Phase 2
    A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
    Enrollment Status: Suspended
    Publish Date: May 27, 2022
    Intervention Type: Biological, Drug, Procedure, Other
    Study Drugs: AllopurinolCytarabineDaunorubicin HydrochlorideVincristine SulfateDexamethasonePegylated L-AsparaginaseMethotrexateCyclophosphamideMercaptopurineRituximabDoxorubicinThioguanineInotuzumab
    Study Phase: Phase 3
    A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
    Enrollment Status: Active, not recruiting
    Publish Date: April 06, 2022
    Intervention Type: Drug
    Study Drug: Uproleselan
    Study Phase: Phase 3
    Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
    Enrollment Status: Completed
    Publish Date: November 26, 2021
    Intervention Type: Radiation, Other, Drug
    Study Phase: Phase 2
    A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
    Enrollment Status: Completed
    Publish Date: March 17, 2021
    Intervention Type: Drug, Other
    Study Phase: Phase 2
    Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
    Enrollment Status: Completed
    Publish Date: July 27, 2020
    Intervention Type: Drug, Procedure, Biological
    Study Phase: Phase 1
    An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
    Enrollment Status: No longer available
    Publish Date: July 15, 2020
    Intervention Type: Drug
    A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia
    Enrollment Status: Completed
    Publish Date: March 17, 2020
    Intervention Type: Genetic, Drug, Procedure, Other
    Study Phase: Phase 2
    A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome
    Enrollment Status: Completed
    Publish Date: March 04, 2019
    Intervention Type: Other, Genetic, Drug
    Study Phase: Phase 1/Phase 2
    A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
    Enrollment Status: Terminated
    Publish Date: February 12, 2019
    Intervention Type: Drug
    Study Phase: Phase 1/Phase 2
    Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
    Enrollment Status: Completed
    Publish Date: January 23, 2019
    Intervention Type: Other, Drug, Procedure
    Study Phase: Phase 2
    A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
    Enrollment Status: Completed
    Publish Date: September 30, 2013
    Intervention Type: Drug, Biological
    Study Phase: Phase 1
    A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies
    Enrollment Status: Completed
    Publish Date: January 11, 2013
    Intervention Type: Drug, Other
    Study Phase: Phase 1
    Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias
    Enrollment Status: Completed
    Publish Date: January 11, 2013
    Intervention Type: Other, Drug
    Study Phase: Phase 1
    A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant
    Enrollment Status: Completed
    Publish Date: January 10, 2013
    Intervention Type: Drug, Other
    Study Phase: Phase 2
    View 20 Less Clinical Trials -
    57 Total Publications
    AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results.
    Journal: Clinical lymphoma, myeloma & leukemia
    Published: September 27, 2022
    Save this doctor for later
    Sign Up
    Looking for the best doctor for you?
    Start Here
    Is this your doctor?
    Find a second opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn more
    Similar Doctors
    AA
    Dr. Anjali S. Advani
    Hematology Oncology
    Elite
    Highly rated in
    30
    conditions
    Hematology Oncology

    Cleveland Clinic Health System

    Main Campus

    9500 Euclid Ave, 
    Cleveland, OH 
     0.9 mi

    Anjali Advani is a Hematologist Oncology expert in Cleveland, Ohio. Advani has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 30 other conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Ohio. Advani is currently accepting new patients.

    AN
    Dr. Aziz Nazha
    Hematology Oncology
    Elite
    Highly rated in
    18
    conditions
    Hematology Oncology

    Jefferson Health

    Cleveland Clinic Main Campus

    9500 Euclid Ave, 
    Cleveland, OH 
     0.9 mi

    Aziz Nazha is a Hematologist Oncology expert in Cleveland, Ohio. Nazha has been practicing medicine for over 16 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in Ohio and Texas.

    JM
    Dr. Jaroslaw P. Maciejewski
    Hematology Oncology
    Elite
    Highly rated in
    36
    conditions
    Hematology Oncology

    Cleveland Clinic Health System

    Cleveland Clinic Main Campus

    9500 Euclid Ave, 
    Cleveland, OH 
     0.9 mi

    Jaroslaw Maciejewski is a Hematologist Oncology expert in Cleveland, Ohio. Maciejewski has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 36 other conditions, according to our data. His top areas of expertise are Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant. He is licensed to treat patients in Ohio. Maciejewski is currently accepting new patients.